NCT07658365

Brief Summary

This study investigates the causal effects of low-intensity transcranial focused ultrasound (tFUS) on odor valence perception and odor-elicited avoidance behaviors in healthy adults. Participants undergo sham and active tFUS targeting the amygdala (AMYG) and ventral striatal olfactory tubercle (VSOT) in a within-subject, randomized, sham-controlled crossover design. Outcomes include subjective odor ratings and objective neurophysiological and behavioral indices of odor valence processing. This research is exploratory and mechanistic in nature and is not intended to evaluate clinical safety or therapeutic efficacy.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at P25-P50 for not_applicable healthy

Timeline
20mo left

Started Sep 2026

Typical duration for not_applicable healthy

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 10, 2026

Completed
12 days until next milestone

First Posted

Study publicly available on registry

June 22, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

September 1, 2026

Expected
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2028

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2028

Last Updated

June 22, 2026

Status Verified

June 1, 2026

Enrollment Period

1.7 years

First QC Date

June 10, 2026

Last Update Submit

June 15, 2026

Conditions

Keywords

healthy volunteerelectroencephalography (EEG)magnetic resonance imaging (MRI)odors

Outcome Measures

Primary Outcomes (4)

  • Odor Valence Rating

    Participant rating of odor pleasantness on a 0-100 mm visual analog scale (e.g., unpleasant → pleasant)

    from the baseline visit until the third follow-up visit (about 1 month)

  • Late Positive Potential

    Mean EEG amplitude (400-800 ms) at centro-parietal sites to olfactory-visual stimuli

    from the baseline visit until the third follow-up visit (about 1 month)

  • Sniff Volume

    Total nasal airflow (in mL) per odor trial, measured via nasal cannula or spirometer

    from the baseline visit until the third follow-up visit (about 1 month)

  • Corrugator Supercilii EMG Activity

    Mean EMG amplitude from facial muscle sensitive to negative affect and aversion

    from the baseline visit until the third follow-up visit (about 1 month)

Secondary Outcomes (3)

  • Odor Intensity Rating

    from the baseline visit until the third follow-up visit (about 1 month)

  • Odor Avoidance Rating

    from the baseline visit until the third follow-up visit (about 1 month)

  • Sniff Rate

    from the baseline visit until the third follow-up visit (about 1 month)

Study Arms (3)

Active tFUS targeting the Amygdala (AMYG)

EXPERIMENTAL

Active tFUS of the bilateral Amygdala randomized at one of the three stimulation visits

Device: transcranial focused ultrasound (tFUS)

Active tFUS targeting the Ventral Striatal Olfactory Tubercle (VSOT)

EXPERIMENTAL

Active tFUS of the bilateral VSOT randomized at one of the three stimulation visits

Device: transcranial focused ultrasound (tFUS)

Sham tFUS

SHAM COMPARATOR

Sham tFUS randomized at one of three stimulation visits

Device: transcranial focused ultrasound (tFUS)

Interventions

non-invasive brain stimulation using tFUS

Active tFUS targeting the Amygdala (AMYG)Active tFUS targeting the Ventral Striatal Olfactory Tubercle (VSOT)Sham tFUS

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18-65 years
  • Healthy adult volunteers
  • Normal olfactory function (Sniffin' Sticks total TDI ≥ 30.75)
  • Ability to provide informed consent
  • English fluency sufficient for task completion

You may not qualify if:

  • MRI or tFUS contraindications (e.g., metal implants, claustrophobia, pregnancy)
  • Sinonasal conditions affecting airflow or smell
  • Current use of medications that alter olfaction
  • Positive urine drug screen

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Houghton DC, Uhde TW, Borckardt JJ, Cortese BM. Exploratory Investigation of a Brief Cognitive Behavioral Intervention and Transcranial Direct Current Stimulation on Odor Sensitivity. Psychosom Med. 2019 May;81(4):389-395. doi: 10.1097/PSY.0000000000000679.

    PMID: 30762663BACKGROUND
  • Badran BW, Gruber EM, O'Leary GH, Austelle CW, Huffman SM, Kahn AT, McTeague LM, Uhde TW, Cortese BM. Electrical stimulation of the trigeminal nerve improves olfaction in healthy individuals: A randomized, double-blind, sham-controlled trial. Brain Stimul. 2022 May-Jun;15(3):761-768. doi: 10.1016/j.brs.2022.05.005. Epub 2022 May 11.

    PMID: 35561963BACKGROUND

MeSH Terms

Conditions

Anosmia

Condition Hierarchy (Ancestors)

Olfaction DisordersSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Nicole Cash, Study Coordinator

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor-Faculty

Study Record Dates

First Submitted

June 10, 2026

First Posted

June 22, 2026

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

April 30, 2028

Study Completion (Estimated)

April 30, 2028

Last Updated

June 22, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will share

Results (raw data and summarized) will be shared. A final de-identified data set will be made available for retrieval and analysis through OpenNeuro.org. All study protocols, including detailed descriptions of the study structure, data formats, and analytical methods, will be made available to ensure transparency and reproducibility. Associated documentation, including data dictionaries, codebooks, and analysis scripts, will be provided to enable others to replicate our methodology and build upon our findings. Data will be made available after publication of the findings.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
Data will be made available after publication of the findings. Data will be retained long enough to support the reproducibility of our published findings, the re-use by others, and as long as it is of value to the research community and/or public.
Access Criteria
Data will be identifiable through a search engine for the title and other key words including the Modality: EEG, Task: odor-enhanced visual processing, Diagnosis: healthy controls, and Study Type: crossover. Additionally, we will provide the Openneuro Accession Number in any study communication.